Overview

CT 327 in the Treatment of Atopic Dermatitis

Status:
Terminated
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
This study will look at how safe and effective, a novel agent, CT 327 cream is in treating patients with mild to moderate atopic dermatitis (AD). Patients will be treated twice daily for 14 days on specific lesions of AD and safety and symptoms of AD will be assessed throughout the treatment period.
Phase:
Phase 2
Details
Lead Sponsor:
Creabilis SA